Study identifier:20-605
ClinicalTrials.gov identifier:NCT04757259
EudraCT identifier:N/A
CTIS identifier:N/A
An Expanded Access Protocol for Patients Who Completed Study 13-601 and Continue to Clinically Benefit from Cerdulatinib
Relapsed/refractory chronic lymphocytic leukemia, Non-hodgkin's Lymphoma
-
-
cerdulatinib
All
-
Expanded Access
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Mar 2024 by Alexion Pharmaceuticals
Alexion Pharmaceuticals
-
No locations available
| Arms | Assigned Interventions |
|---|